The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Clinical research

Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial

EuroIntervention 2010;6:447-453 published online ahead of print June 2010.

1. Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands; 2. Auckland City Hospital, Auckland, New Zealand; 3. Skejby Sygehus, Aarhus University Hospital, Skejby, Denmark; 4. Jagiellonian University, Krakow, Poland; 5. Abbott Vascular, Diegem,

Aims: Multimodality imaging of the first-in-man trial using a fully resorbable everolimus-eluting scaffold (BVS, Abbott Vascular, Santa Clara, CA, USA) demonstrated at two years the bioreso

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Impact of right coronary artery disease on mortality in patients undergoing percutaneous coronary intervention of unprotected left main coronary artery disease